Swiss healthtech startup Hedera Dx has secured €15 million in a Series A funding round to scale its precision oncology platform, designed to help hospitals offer advanced cancer diagnostics and treatments.
The round was led by Vsquared Ventures, with new investor Tesi joining in. Returning backers include Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest.
Improving access to targeted cancer therapies
Founded in 2021, Hedera Dx aims to close the gap in global access to precision cancer care. Its platform combines liquid biopsy testing with real-world clinical data to guide cancer treatment decisions and drug development. The company’s blood-based cancer tests are already deployed in hospital labs across 11 European countries.
“Our goal is to make sophisticated molecular diagnostics accessible at the local level, enabling more hospitals to offer personalised care without relying on centralised labs,” said CEO and co-founder Tommi Lehtonen.
Advertisement
Data-driven infrastructure for hospitals
With a team of over 20 experts spanning genomics, oncology, bioinformatics, and AI, Hedera Dx is building infrastructure to empower hospital laboratories to run advanced molecular testing in-house. This reduces cost, speeds up diagnosis, and opens the door to targeted cancer treatments for more patients.
Co-founder and Chief Medical Officer Dr. Christian Meisel added, “We’re not just expanding access to care—we’re creating a real-world data platform that can drive the next wave of cancer treatment innovation.”
Investor confidence in healthtech
Vsquared Ventures, known for backing deeptech solutions to global problems, highlighted Hedera’s strategic position in precision medicine beyond the US market. Tesi’s participation further strengthens Hedera Dx’s support network as it scales operations in Europe and beyond.
The funds will be used to expand clinical adoption, enhance diagnostics capabilities, and deepen partnerships with hospitals to broaden access to life-saving oncology technologies.
